CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
拓展 CAR-T 细胞治疗的视野：从肿瘤治疗到自身免疫性疾病及更广泛领域
英文原题：Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.
查看英文原题
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T细胞疗法因其对白血病和淋巴瘤等血液系统恶性肿瘤治疗的变革性影响而受到广泛关注。尽管取得了显著成功，但耐药性、在实体瘤中疗效有限以及不良副作用等挑战仍然突出。本综述整合了CAR-T 细胞疗法的最新进展，并探讨了克服免疫抑制性肿瘤微环境（TME）的创新工程技术和策略。我们还讨论了超越癌症的新兴应用，包括自身免疫性疾病和慢性感染。未来展望强调开发更有效、特异性更强、持久性更高且毒性更低的CAR-T 细胞，为下一代免疫疗法提供路线图。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T-cell therapy has garnered significant attention for its transformative impact on the treatment of hematologic malignancies such as leukemia and lymphoma. Despite its remarkable success, challenges such as resistance, limited efficacy in solid tumors, and adverse side effects remain prominent. This review consolidates recent advancements in CAR-T-cell therapy and explores innovative engineering techniques and strategies to overcome the immunosuppressive tumor microenvironment (TME).
We also discuss emerging applications beyond cancer, including autoimmune diseases and chronic infections. Future perspectives highlight the development of more potent CAR-T cells with increased specificity and persistence and reduced toxicity, providing a roadmap for next-generation immunotherapies.
论文信息
- 作者
- Yang Z、Ha B、Wu Q、Ren F、Yin Z、Zhang H
- 第一作者单位
- Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.China
- 通讯作者单位
- State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Sciences, Cancer Biology Center, College of Life Sciences, Nankai University, Tianjin, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40046061 · DOI 10.3389/fimmu.2025.1544532
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →